Cargando…

Anti-gp41 antibodies inhibit infection and transcytosis of HIV-1 infectious molecular clones expressing transmitted/founder envelopes

Detalles Bibliográficos
Autores principales:	Jain, S, Ochsenbauer, C, Kappes, JC, Rosenthal, KL
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441676/ http://dx.doi.org/10.1186/1742-4690-9-S2-P195

Ejemplares similares

P20-15. Evaluation of HIV-1 subtype B acute envelope-expressing infectious molecular clones
por: Siddiqui, AA, et al.
Publicado: (2009)

P05-04. Neutralizing antibodies induced by immunization with liposomal gp41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes
por: Matyas, GR, et al.
Publicado: (2009)

HIV-1 Expressing the Envelopes of Transmitted/Founder or Control/Reference Viruses Have Similar Infection Patterns of CD4 T-Cells in Human Cervical Tissue Ex Vivo
por: Merbah, Melanie, et al.
Publicado: (2012)

Generation and characterization of infectious molecular clones of transmitted/founder HIV-1 subtype C viruses
por: Luthuli, Bonisile, et al.
Publicado: (2023)

Uterine Epithelial Cell Regulation of DC-SIGN Expression Inhibits Transmitted/Founder HIV-1 Trans Infection by Immature Dendritic Cells
por: Ochiel, Daniel O., et al.
Publicado: (2010)

HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
por: Verkoczy, Laurent, et al.
Publicado: (2014)

A novel mechanism of HIV transcytosis and infection
por: Gupta, S, et al.
Publicado: (2012)

Virus-like particles highly expressing DC-SIGN concentrate trimeric HIV-envelope proteins with noncovalently linked immunoreactive gp120 and gp41
por: Vyas, GN
Publicado: (2012)

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C
por: Fouda, G, et al.
Publicado: (2012)

Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted / founder sensitivity to broadly neutralizing antibodies
por: Ratnapriya, Sneha, et al.
Publicado: (2023)

A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer
por: Ananthaswamy, Neeti, et al.
Publicado: (2019)

Assessing the protective efficacy of antibodies to the HIV gp41 region by active vaccination
por: Sharma, SK, et al.
Publicado: (2012)

Immunisation with the membrane proximal external region of gp41 of HIV-1 grafted into the transmembrane envelope protein of a gammaretrovirus
por: Strasz, N, et al.
Publicado: (2012)

Assessment of a diverse panel of transmitted/founder HIV-1 infectious molecular clones in a luciferase based CD8 T-cell mediated viral inhibition assay
por: Fernandez, Natalia, et al.
Publicado: (2022)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Membrane topology analysis of HIV-1 envelope glycoprotein gp41
por: Liu, Shujun, et al.
Publicado: (2010)

Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein
por: Joshi, Vinita R., et al.
Publicado: (2020)

Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles
por: Kumar, Sonu, et al.
Publicado: (2021)

Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
por: Williams, WB, et al.
Publicado: (2012)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
por: Sanders, Rogier W, et al.
Publicado: (2004)

Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope
por: Penn-Nicholson, Adam, et al.
Publicado: (2008)

Differential glycosylation of envelope gp120 affects reactivity with HIV-1 specific antibodies
por: Czernekova, Lydie, et al.
Publicado: (2014)

P11-20. HIV-1 gp41-specific mucosal IgAs from highly exposed but IgG seronegative women block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection
por: Tudor, D, et al.
Publicado: (2009)

Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones
por: Miglietta, Riccardo, et al.
Publicado: (2014)

Identification of variant HIV envelope proteins with enhanced affinities for precursors to anti-gp41 broadly neutralizing antibodies
por: Zhu, Hong, et al.
Publicado: (2019)

Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes
por: Pollara, J, et al.
Publicado: (2012)

Envelope Deglycosylation Enhances Antigenicity of HIV-1 gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies
por: Ma, Ben-Jiang, et al.
Publicado: (2011)

OA021-04. HIV-1 gp41 envelope MPER mutation altered epitope conformation in lipid and increased sensitivity to 2F5 and 4E10 neutralizing antibodies
por: Shen, X, et al.
Publicado: (2009)

A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence
por: Welbourn, Sarah, et al.
Publicado: (2022)

454 pyrosequencing and bioinformatics analysis of the lineage of the broad and potent gp41-directed antibody 10e8
por: Ofek, G, et al.
Publicado: (2012)

Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development
por: Polonis, V, et al.
Publicado: (2012)

HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
por: Kovacs, JM, et al.
Publicado: (2012)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis
por: Duchemin, Maxence, et al.
Publicado: (2018)

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes
por: O’Brien, Sean P., et al.
Publicado: (2019)

VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120
por: Smith, S. Abigail, et al.
Publicado: (2019)

Maternal Envelope gp41 Ectodomain-Specific Antibodies Are Associated With Increased Mother-to-Child Transmission of Human Immunodeficiency Virus-1
por: Naiman, Nicole E, et al.
Publicado: (2020)

A deeper view of transmitted/founder viruses using 454 whole genome deep sequencing
por: Tully, DC, et al.
Publicado: (2012)

P04-41. Kinetics of antibody neutralization and viral evolution following envelope vaccination in SIV-infected rhesus monkeys
por: Basavapathruni, A, et al.
Publicado: (2009)

DNA vaccines that express the MPER of HIV-1 gp41 elicit different antibodies depending upon their transmembrane and cytoplasmic domains
por: Scott, JK, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_tv0q0hvdh7qkjjrkcth15t3su8